This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
HCV Infection
and you are
between 18 and 70
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of GS-9857 in adults with normal and impaired hepatic function. Adults in the healthy control group will be matched to adults with impaired hepatic function by gender, age (± 10 years), and body mass index (± 15%).

Provided treatments

  • Drug: GS-9857
Tris trial is registered with FDA with number: NCT02397707. The sponsor of the trial is Gilead Sciences and it is looking for 33 volunteers for the current phase.
Official trial title:
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment